Association of decreased NK cell activity and IFNγ expression with pSTAT dysregulation in breast cancer patients

Journal of B.U.ON.

Volumn 16, Issue 2, 2011, Pages 219-226

  Konjevic, Gordana ^a,b   Radenkovic, S ^a   Srdic, T ^a   Jurisic, V ^c   Stamatovic, Lj ^a   Milovic, M ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Breast cancer; IFN ; Natural killer cells; pSTAT 1, 3 and 5

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CELL ACTIVITY; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTES; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 79960262720     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J et al. Interferon-gamma and cancer immunoediting. Immunol Res 2005; 32: 231-245.
2. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109. (Pubitemid 34229385)
3. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 2001;410:1107-1111. (Pubitemid 32391043)
4. Robertson MJ, Ritz J. Biology and relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
5. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112-117.
6. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD 16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999; 96: 5640-5644.
7. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359-393. (Pubitemid 28183369)
8. Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, Spuzic I. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis 2003; 20: 647-655. (Pubitemid 37463902)
9. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274. (Pubitemid 40563170)
10. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol 2001; 22: 633-640. (Pubitemid 33043908)
11. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann Rev Immunol 1999; 17: 189-220.
12. Smyth MJ, Thia KY, Street SE, McGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-760.
13. Smyth MJ, Cretney E, Takeda K et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 661-670. (Pubitemid 32524460)
14. Ciszak L, Kosmaczewska A, Werynska B, Szteblich A, Jankowska R, Frydecka I. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep 2009; 21: 173-184.
15. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001; 166: 2276-2282. (Pubitemid 32173458)
16. Lesinski GB, Kondadasula SV, Crespin T et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J Natl Cancer Inst 2004; 96: 1331-1342. (Pubitemid 39264122)
17. Varker KA, Kondadasula SV, Go MR et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006; 12: 5850-5858. (Pubitemid 44629618)
18. Critchley-Thorne RJ, Simons DL, Yan N et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 2009; 106: 9010-9015.
19. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177: 896-904. (Pubitemid 44036590)
20. Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 2001; 66: 255-263. (Pubitemid 32675028)
21. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24: 312-317. (Pubitemid 350135953)
22. Horr B, Borck H, Thurmond R, Grösch S, Diel F. STAT1 phosphorylation and cleavage is regulated by the histamine (H4) receptor in human atopic and non-atopic lymphocytes. Int Immunopharmacol 2006; 6: 1577-1585.
23. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J (Eds.): Manual of Clinical Laboratory Immunology (3rd Edn). American Society for Microbiology, Washington DC, 1986, pp 226-235.
24. Rostaing L, Tkaczuk J, Durand M et al. Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry 1999; 35: 318-328. (Pubitemid 29160230)
25. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90: 1-50. (Pubitemid 43765795)
26. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11: 571-611. (Pubitemid 23115018)
27. Kiladjian JJ, Bourgeois E, Lobe I et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463-470. (Pubitemid 43291745)
28. Konjevic G, Spuzic I. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma 1993; 40: 81-85. (Pubitemid 23173963)
29. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 2007; 18: 159-170. (Pubitemid 46420551)
30. Kile BT, Nicola NA, Alexander WS. Negative regulators of cytokine signaling. Int J Hematol 2001; 73: 292-298.